Valuation: Pluristem Therapeutics

Market Cap 22.55M 19.73M 18.19M 16.86M 32M 2.14B 32.52M 218M 84.8M 1.06B 84.66M 82.83M 3.65B P/E 2024
-1.45x
P/E 2025 -1.39x
Enterprise Value 35.99M 31.49M 29.02M 26.9M 51.07M 3.42B 51.89M 348M 135M 1.69B 135M 132M 5.83B EV / Sales 2024
93.2x
EV / Sales 2025 39.1x
Free-Float
53.44%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 28/03/2017
Director of Finance/CFO 42 30/11/2022
Chief Operating Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 54 31/01/2015
Director/Board Member 56 05/01/2021
Director/Board Member 64 31/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 23.52M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.25%+1.70%+419.39%+621.71% 40.39B
-0.16%+8.42%+28.20%+63.00% 34.4B
+1.10%+7.77%+28.18%-3.96% 34.38B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.35%+0.09% - - 16.64B
-3.33%+3.15%+71.30%+131.94% 16.14B
+3.79%+8.88%+106.63%+106.63% 13.75B
+0.32%+0.53%+14.33%+21.47% 13.71B
Average +0.53%+4.73%+84.51%+123.01% 27.33B
Weighted average by Cap. +0.09%+5.08%+95.81%+141.26%

Financials

2024 2025
Net sales 326K 285K 263K 244K 463K 30.94M 470K 3.15M 1.23M 15.27M 1.22M 1.2M 52.78M 1.34M 1.17M 1.08M 999K 1.9M 127M 1.93M 12.92M 5.02M 62.58M 5.02M 4.91M 216M
Net income -20.89M -18.28M -16.85M -15.61M -29.64M -1.98B -30.12M -202M -78.55M -978M -78.42M -76.72M -3.38B -22.58M -19.76M -18.21M -16.88M -32.05M -2.14B -32.56M -218M -84.93M -1.06B -84.78M -82.95M -3.66B
Net Debt -373K -326K -301K -279K -529K -35.4M -538K -3.61M -1.4M -17.47M -1.4M -1.37M -60.39M 13.44M 11.76M 10.84M 10.04M 19.07M 1.28B 19.37M 130M 50.53M 629M 50.45M 49.35M 2.18B
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-